Evidence map›Paper›PMID 40276762›Full record

ArticleiScience2025

Modeling hepatic steatosis with human adult stem cell-derived liver organoids.

Liuyang Zhu, Sen Liu, Ze Wang, Yueyue Yang, Pinsheng Han, Wen Tong, Tianyu Zhao, Libo Wang, Tao Cui, Long Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Biobanked Liver Organoids: A Roadmap for Precision Hepatology.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liuyang ZhuFirst Central Clinical College of Tianjin Medical University, Tianjin 300070, China.
Sen LiuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.
Ze WangState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Yueyue YangCollege of Life Sciences, Nankai University, Tianjin 300071, China.
Pinsheng HanNankai University of Medicine College, Tianjin 300071, China.
Wen TongFirst Central Clinical College of Tianjin Medical University, Tianjin 300070, China.
Tianyu ZhaoState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Libo WangState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin 300000, China.
Tao CuiTianhui Biotechnology Co., Ltd., Hefei 230000, China.
Long YangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains the most common chronic liver disease worldwide, and appropriate

Indexed as

Cellular physiologyDiseaseHuman metabolismOrganizational aspects of cell biologySpecialized functions of cellsStem cells research

Identifiers

PMID40276762
PMCPMC12019286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.